These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 36148567)

  • 1. Relationship of Long Acting Injectable Antipsychotics with Caregiver Burden, Quality of Life, Symptom Severity and Treatment Discontinuation in Schizophrenia.
    Uysal F; Yildizhan E; Tomruk NB
    Turk Psikiyatri Derg; 2022; 33(3):167-179. PubMed ID: 36148567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical evolution of patients treated with aripiprazole long-acting injectable: a preliminary, prospective, observational study.
    García Álvarez JC; González Sánchez L; García Resa E; Bonete Llácer JM; Román Rodríguez A; Pecino Esquerdo B; Pérez Martínez E
    Int J Psychiatry Clin Pract; 2020 Mar; 24(1):10-17. PubMed ID: 31933402
    [No Abstract]   [Full Text] [Related]  

  • 3. Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study.
    Joo SW; Shon SH; Choi G; Koh M; Cho SW; Lee J
    Eur Neuropsychopharmacol; 2019 Sep; 29(9):1051-1060. PubMed ID: 31362852
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of type of treatment on the well-being of Spanish patients with schizophrenia and their caregivers.
    Fe Bravo-Ortiz M; Gutiérrez-Casares JR; Rodríguez-Morales A; García MA; Hidalgo-Borrajo R
    Int J Psychiatry Clin Pract; 2011 Nov; 15(4):286-95. PubMed ID: 22122003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge.
    Marcus SC; Zummo J; Pettit AR; Stoddard J; Doshi JA
    J Manag Care Spec Pharm; 2015 Sep; 21(9):754-68. PubMed ID: 26308223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder.
    Greene M; Yan T; Chang E; Hartry A; Touya M; Broder MS
    J Med Econ; 2018 Feb; 21(2):127-134. PubMed ID: 28895758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of long-acting injectable antipsychotic treatment discontinuation in outpatients with schizophrenia: relevance of the Drug Attitude Inventory-10.
    Tatini L; D'Anna G; Pietrini F; Calligaris E; Ballerini A; Ricca V
    Int Clin Psychopharmacol; 2021 Jul; 36(4):181-187. PubMed ID: 33902086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study.
    Llorca PM; Bobes J; Fleischhacker WW; Heres S; Moore N; Bent-Ennakhil N; Sapin C; Loze JY; Nylander AG; Patel MX
    Eur Psychiatry; 2018 Aug; 52():85-94. PubMed ID: 29734130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Self- and caregiver-perceived disability, subjective well-being, quality of life and psychopathology improvement in long-acting antipsychotic treatments: a 2-year follow-up study.
    Pietrini F; Tatini L; Santarelli G; Brugnolo D; Squillace M; Bozza B; Ballerini A; Ricca V; D'Anna G
    Int J Psychiatry Clin Pract; 2021 Sep; 25(3):307-315. PubMed ID: 34057873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between telomere length and efficacy of oral and long-acting injectable antipsychotics on severity and cognitive impairment of schizophrenia.
    Pippal N; Halder S; Srivastava S; Kar R; Gupta R; Anthonio AE
    Int J Psychiatry Clin Pract; 2022 Jun; 26(2):157-164. PubMed ID: 34715000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adherence to depot versus oral antipsychotic medication in schizophrenic patients during the long-term therapy.
    Stanković Z; Ille T
    Vojnosanit Pregl; 2013 Mar; 70(3):267-73. PubMed ID: 23607237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia.
    Potkin S; Bera R; Zubek D; Lau G
    BMC Psychiatry; 2013 Oct; 13():261. PubMed ID: 24131801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia.
    Song X; El Khoury AC; Brouillette M; Smith D; Joshi K
    J Med Econ; 2019 Nov; 22(11):1105-1112. PubMed ID: 31062998
    [No Abstract]   [Full Text] [Related]  

  • 14. Changes in attitude towards LAI antipsychotic maintenance treatment: A two-year follow-up study.
    Pietrini F; D'Anna G; Tatini L; Talamba GA; Andrisano C; Calderani E; Manetti M; Rossi Prodi P; Ricca V; Ballerini A
    Eur Psychiatry; 2018 Sep; 53():58-65. PubMed ID: 29957369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attitudes of European physicians towards the use of long-acting injectable antipsychotics.
    Patel MX; Bent-Ennakhil N; Sapin C; di Nicola S; Loze JY; Nylander AG; Heres S
    BMC Psychiatry; 2020 Mar; 20(1):123. PubMed ID: 32169077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subjective well-being, drug attitude, and changes in symptomatology in chronic schizophrenia patients starting treatment with new-generation antipsychotic medication.
    Widschwendter CG; Kemmler G; Rettenbacher MA; Yalcin-Siedentopf N; Hofer A
    BMC Psychiatry; 2018 Jun; 18(1):212. PubMed ID: 29954366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.
    Llorca PM; Abbar M; Courtet P; Guillaume S; Lancrenon S; Samalin L
    BMC Psychiatry; 2013 Dec; 13():340. PubMed ID: 24359031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of discontinuation and hospitalization during long-acting injectable antipsychotic treatment in patients with schizophrenia spectrum disorder.
    Üçok A; Yağcioğlu EA; Aydin M; Kara İA; Erbasan V; Türkoğlu Ö; Ergün S; Chousein MG; Oktar N; Uçar N; Köroğlu BS; Ozan E
    Int Clin Psychopharmacol; 2021 Mar; 36(2):89-96. PubMed ID: 33512962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
    Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
    J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.